Journal of Clinical Medicine (May 2024)
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
- Laura Pini,
- Diego Bagnasco,
- Bianca Beghè,
- Fulvio Braido,
- Paolo Cameli,
- Marco Caminati,
- Cristiano Caruso,
- Claudia Crimi,
- Gabriella Guarnieri,
- Manuela Latorre,
- Francesco Menzella,
- Claudio Micheletto,
- Andrea Vianello,
- Dina Visca,
- Benedetta Bondi,
- Yehia El Masri,
- Jordan Giordani,
- Andrea Mastrototaro,
- Matteo Maule,
- Alessandro Pini,
- Stefano Piras,
- Martina Zappa,
- Gianenrico Senna,
- Antonio Spanevello,
- Pierluigi Paggiaro,
- Francesco Blasi,
- Giorgio Walter Canonica,
- on behalf of the SANI Study Group
Affiliations
- Laura Pini
- ASST Spedali Civili of Brescia, 25123 Brescia, Italy
- Diego Bagnasco
- Allergy and Respiratory Diseases Clinic, IRCCS Policlinico San Martino, 16132 Genova, Italy
- Bianca Beghè
- Department of Medical and Surgical Sciences, Maternal, Infant and Adult, University of Modena and Reggio Emilia, 41124 Modena, Italy
- Fulvio Braido
- Allergy and Respiratory Diseases Clinic, IRCCS Policlinico San Martino, 16132 Genova, Italy
- Paolo Cameli
- Respiratory Diseases Unit, Department of Medical Sciences, Azienda Ospedaliera-Universitaria Senese, 53100 Siena, Italy
- Marco Caminati
- Department of Medicine, University of Verona, 37134 Verona, Italy
- Cristiano Caruso
- Allergologic Unit, Policlinico Agostino Gemelli, 00168 Rome, Italy
- Claudia Crimi
- Respiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, Italy
- Gabriella Guarnieri
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, 35122 Padova, Italy
- Manuela Latorre
- Pneumologic Unit, Department of Medical Specialties, Nuovo Ospedale delle Apuane, 54100 Massa, Italy
- Francesco Menzella
- Pneumologic Unit, Ospedale di Montebelluna, 31044 Montebelluna, Italy
- Claudio Micheletto
- Pneumologic Unit, Ospedale Borgo Trento, 37126 Verona, Italy
- Andrea Vianello
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, 35122 Padova, Italy
- Dina Visca
- Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, 21100 Varese, Italy
- Benedetta Bondi
- Allergy and Respiratory Diseases Clinic, IRCCS Policlinico San Martino, 16132 Genova, Italy
- Yehia El Masri
- Department of Clinical and Experimental Sciences, University of Brescia, 25122 Brescia, Italy
- Jordan Giordani
- Department of Clinical and Experimental Sciences, University of Brescia, 25122 Brescia, Italy
- Andrea Mastrototaro
- Department of Medicine, University of Verona, 37134 Verona, Italy
- Matteo Maule
- Asthma Center and Allergy Unit, Verona University Hospital, 37126 Verona, Italy
- Alessandro Pini
- Department of Emergency, Anaesthesiological and Resuscitation Sciences, University Cattolica Sacro Cuore, 29122 Rome, Italy
- Stefano Piras
- Department of Clinical and Experimental Sciences, University of Brescia, 25122 Brescia, Italy
- Martina Zappa
- Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, 21100 Varese, Italy
- Gianenrico Senna
- Department of Medicine, University of Verona, 37134 Verona, Italy
- Antonio Spanevello
- Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, 21100 Varese, Italy
- Pierluigi Paggiaro
- Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, 56124 Pisa, Italy
- Francesco Blasi
- Department of Pathophysiology and Transplantation, University of Milano, 20122 Milan, Italy
- Giorgio Walter Canonica
- Personalized Medicine Center, Asthma and Allergology, Humanitas Research Hospital, 20089 Rozzano, Italy
- on behalf of the SANI Study Group
- DOI
- https://doi.org/10.3390/jcm13103013
- Journal volume & issue
-
Vol. 13,
no. 10
p. 3013
Abstract
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased the forced expiratory volume in 1 second (FEV1) (+440 mL at 36 months, p Conclusions: Benralizumab improved asthma and sinonasal outcomes up to 36 months. These findings support the potential of benralizumab to induce CR, emphasizing its role as a disease-modifying anti-asthmatic drug for the management of SEA. Further research is warranted to expand these findings by minimizing data loss and assessing benralizumab’s long-term safety.
Keywords